The Senate Committee on Commerce, Science, and Transportation passed the NASA Authorization Act of 2026 on a unanimous voice vote, and the 200-page bill reads like a government that suddenly remembered it has a space agency worth funding. It’s the most significant congressional direction NASA has received since at least 2022, and it lands at a moment when the Artemis program is being reshaped from within and pressured from without.
The bill codifies changes NASA Administrator Jared Isaacman already set in motion at a February 27 Artemis update that surprised even close observers. SLS stays alive, but the costly Exploration Upper Stage is dead. The Block 1B variant dies with it.
Instead, NASA will pursue a “near Block 1” upgrade using a commercially sourced upper stage, likely from United Launch Alliance’s Centaur V or Blue Origin’s New Glenn stage. Three billion dollars already spent on EUS becomes a sunk cost lesson.
Isaacman wants SLS launching every 10 months instead of every three years. That’s Apollo-era cadence, and it’s wildly ambitious for a rocket whose second flight is currently sitting back inside the Vehicle Assembly Building at Kennedy Space Center with a balky helium pressurization system. Artemis 2 was rolled back from the pad on February 25 after the issue couldn’t be resolved in place.
NASA is eyeing an April launch window, but nobody’s making promises.
The bigger surprise from the Artemis restructuring was inserting an entirely new Earth-orbit mission between the current Artemis 2 and the first lunar landing attempt. The old Artemis 3 lunar landing becomes Artemis 4, targeted for 2028. The new Artemis 3, slated for 2027, will test one or both Human Landing System vehicles — Blue Origin’s Blue Moon Mark 2 and SpaceX’s Starship HLS — in Earth orbit, where a crew can bail out fast if something goes wrong.
Under the old plan, SpaceX’s lander would have carried astronauts to the lunar surface without ever being crewed in orbit first.
The Senate bill embraces all of this and goes further. It extends the International Space Station’s operational life to at least 2032, buying commercial station developers two more years to get their hardware flying. It mandates that NASA keep allowing private missions to the ISS and accelerate requests for proposals on commercial replacements.
Congress also reinstated three senior positions the Trump administration eliminated in early 2025 — chief scientist, chief technologist, and chief economist — and devoted substantial ink to reaffirming that science remains a strategic national interest. Mars Sample Return, killed in the 2026 budget, gets resurrected. The bill even directs NASA to send human tissue samples to Mars, which is either forward-thinking biology or the opening scene of a film nobody asked for.
Then there’s China. The bill bars NASA from any cooperation with Chinese space entities and prohibits Chinese officials from setting foot in a NASA facility. Russia, notably, gets no such treatment.
Whether this reflects genuine strategic concern or performative toughness is an exercise left to the reader, but it’s written into law if this passes.
The authorization act arrives at a peculiar inflection point. A year ago, NASA looked like it might get hollowed out. Isaacman’s appointment raised eyebrows given his commercial ties, but his management style — confronting Boeing’s Starliner failures head-on, restructuring Artemis with an engineer’s pragmatism — has earned grudging respect.
He’s borrowing directly from Apollo’s incremental playbook: fly what you know, test before you trust, build capability step by step.
The Senate seems to agree. Unanimous voice votes on 200-page space bills don’t happen by accident. They happen when both parties decide the political cost of opposing lunar ambitions outweighs whatever budget reservations they harbor.
NASA still has to execute. SLS still has to fly reliably. Commercial landers still have to work.
But for the first time in a long time, the agency has a government telling it clearly what to do — and, more importantly, telling it to keep doing science while it does it. That’s not a small thing for an agency that spent the last year wondering if it still had a mission at all.
Share this Story